Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NILOTINIB Cause Incorrect product administration duration? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Incorrect product administration duration have been filed in association with NILOTINIB (nilotinib). This represents 0.0% of all adverse event reports for NILOTINIB.

6
Reports of Incorrect product administration duration with NILOTINIB
0.0%
of all NILOTINIB reports
1
Deaths
3
Hospitalizations

How Dangerous Is Incorrect product administration duration From NILOTINIB?

Of the 6 reports, 1 (16.7%) resulted in death, 3 (50.0%) required hospitalization, and 2 (33.3%) were considered life-threatening.

Is Incorrect product administration duration Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NILOTINIB. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does NILOTINIB Cause?

Death (2,667) Fatigue (1,679) Rash (1,250) Nausea (1,180) Headache (1,177) Pain (1,169) Dyspnoea (1,070) Diarrhoea (998) Drug ineffective (992) Malaise (961)

What Other Drugs Cause Incorrect product administration duration?

ETONOGESTREL (3,974) POLYETHYLENE GLYCOL 3350 (2,129) NIRMATRELVIR\RITONAVIR (744) DOCOSANOL (634) LANSOPRAZOLE (564) LOPERAMIDE (543) NAPROXEN (499) INSULIN LISPRO (479) DICLOFENAC (362) OMEPRAZOLE (302)

Which NILOTINIB Alternatives Have Lower Incorrect product administration duration Risk?

NILOTINIB vs NIMESULIDE NILOTINIB vs NIMODIPINE NILOTINIB vs NINTEDANIB NILOTINIB vs NINTEDANIB ESYLATE NILOTINIB vs NIRAPARIB

Related Pages

NILOTINIB Full Profile All Incorrect product administration duration Reports All Drugs Causing Incorrect product administration duration NILOTINIB Demographics